Overview

Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Subjects

Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, placebo- and positive-controlled, parallel group, 3-arm study to assess the potential for therapeutic and supratherapeutic concentrations of setmelanotide to affect the QTcF interval compared with placebo.
Phase:
Phase 4
Details
Lead Sponsor:
Rhythm Pharmaceuticals, Inc.
Treatments:
Moxifloxacin